Ruxolitinib in Seborrheic Dermatitis

NCT05787860 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Seborrheic Dermatitis

Interventions

DRUG: Ruxolitinib 1.5% Cream

Sponsor

Icahn School of Medicine at Mount Sinai

Collaborators

[object Object]